- Molecular NameVidarabine
- Synonym9-beta-D-arabinofuranosyl-adenine; Adenine Arabinoside; Ara Atp; Ara-A; Ara-a Triphosphate; Ara-Atp; Araadenosine; Arabinofuranosyladenine Triphosphate; Arabinoside Adenine; Arabinosyl Adenine; Arabinosyl-Atp; Arabinosyladenine; Arabinosyladenine Triphosphate; Vidarabine Triphosphate
- Weight267.245
- Drugbank_IDDB00194
- ACS_NO24356-66-9
- Show 2D model
- LogP (experiment)-1.11
- LogP (predicted, AB/LogP v2.0)-1.22
- pkaN/A
- LogD (pH=7, predicted)-1.22
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.69
- LogSw (predicted, AB/LogsW2.0)5.27
- Sw (mg/ml) (predicted, ACD/Labs)5.43
- No.of HBond Donors5
- No.of HBond Acceptors9
- No.of Rotatable Bonds2
- TPSA139.54
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antiviral drug which is active against herpes simplex and varicella zoster viruses.
- Absorption_value0.0
- Absorption (description)Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions.
- Caco_2N/A
- Bioavailability0.0
- Protein binding31.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn laboratory animals, vidarabine is rapidly deaminated in the gastrointestinal tract to Ara-Hx.
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAcute massive overdosage by oral ingestion of the ophthalmic ointment has not occurred. However, the rapid deamination to arabinosylhypoxanthine should preclude any difficulty. The oral LD50 for vidarabine is greater than 5020 mg/kg in mice and rats. No untoward effects should result from ingestion of the entire contents of the tube. Overdosage by ocular instillation is unlikely because any excess should be quickly expelled from the conjunctival sac.
- LD50 (rat)N/A
- LD50 (mouse)N/A